Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

No Definitive Link Found Between Physical Activity and Prostate Cancer

March 1, 2018
By Dave Levitan
Article

A meta-analysis was unable to find a conclusive relationship between physical activity and the risk of prostate cancer, though a reduced risk was suggested.

A large meta-analysis was unable to find a conclusive relationship between levels of physical activity and the risk of prostate cancer, though some suggestion of reduced risk was seen for occupational activity and for some specific cancer subtypes. There was also indication that physical activity after diagnosis of prostate cancer might have a protective effect.

“Knowledge about risk factors of prostate cancer is limited, complicating the formulation of appropriate strategies for the prevention of prostate cancer,” wrote study authors led by Daniela Schmid, MSc, of the University of Regensburg in Germany. “The role of potential modifiable risk factors for the development of prostate cancer such as obesity, smoking, poor diet, and physical activity is less well understood.”

The authors conducted a meta-analysis and review of studies of physical activity and prostate cancer, including 48 cohort studies and 24 case-control studies incorporating a total of 151,748 cases of prostate cancer. The mean age of the study participants at baseline was 61 years. Results were published in Annals of Oncology.

The primary analysis relating physical activity to prostate cancer revealed an association that was close to null, with a relative risk (RR) of 0.99 (95% CI, 0.94–1.04) comparing the highest and lowest categories of activity. The same held true when the case-control and the cohort studies were examined separately.

They then stratified by the domain of physical activity, and found a significant inverse association between long-term occupational activity and total prostate cancer incidence, with an RR of 0.83 (95% CI, 0.71–0.98) and a borderline association with short-term occupational physical activity with an RR of 0.85 (95% CI, 0.72–1.00). However, the long-term significant RR did not remain significant after removal of individual studies from the analysis.

When stratifying by both type of physical activity and subtypes of prostate cancer, further associations were seen. There was an inverse association between long-term recreational physical activity and advanced/aggressive prostate cancer, with an RR of 0.75 (95% CI, 0.60–0.95), though this incorporated only 2 studies. There was also an inverse association between long-term occupational physical activity and non-advanced/non-aggressive prostate cancer, with an RR of 0.51 (95% CI, 0.37–0.71), again with 2 studies.

There was no association seen between pre-diagnosis physical activity and mortality due to prostate cancer. However, there was an inverse association between physical activity after diagnosis and prostate cancer mortality among survivors, with an RR of 0.69 (95% CI, 0.55–0.85), based on 4 studies.

“These associations may represent an indication for a potential protective effect of long-term activity on prostate cancer incidence,” the authors wrote. “However, our findings must be interpreted with caution.” The analysis’s sensitivity to removal of individual studies, and the small number of studies that revealed some of the significant results, make interpretation difficult. “Despite a growing body of literature on physical activity and prostate cancer incidence, evidence for a link between overall physical activity and risk of prostate cancer remains elusive.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Roman Fabbricatore
August 1st 2025
Article

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
August 1st 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Tim Cortese
August 1st 2025
Article

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 1st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Early Efficacy Seen With Gedatolisib-Based Therapies in Prostate/Breast Cancers

Tim Cortese
August 1st 2025
Article

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.


225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer

Tim Cortese
August 1st 2025
Article

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Related Content

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Roman Fabbricatore
August 1st 2025
Article

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
August 1st 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Tim Cortese
August 1st 2025
Article

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 1st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Early Efficacy Seen With Gedatolisib-Based Therapies in Prostate/Breast Cancers

Tim Cortese
August 1st 2025
Article

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.


225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer

Tim Cortese
August 1st 2025
Article

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.